GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Enterprise Value

AgeX Therapeutics (AgeX Therapeutics) Enterprise Value : $31.78 Mil (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AgeX Therapeutics's Enterprise Value is $31.78 Mil. AgeX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.91 Mil. Therefore, AgeX Therapeutics's EV-to-EBIT ratio for today is -3.21.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AgeX Therapeutics's Enterprise Value is $31.78 Mil. AgeX Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.78 Mil. Therefore, AgeX Therapeutics's EV-to-EBITDA ratio for today is -3.25.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AgeX Therapeutics's Enterprise Value is $31.78 Mil. AgeX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.14 Mil. Therefore, AgeX Therapeutics's EV-to-Revenue ratio for today is 223.79.


AgeX Therapeutics Enterprise Value Historical Data

The historical data trend for AgeX Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Enterprise Value Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 68.52 62.78 53.93 38.32 18.52

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.32 54.82 66.53 27.52 18.52

Competitive Comparison of AgeX Therapeutics's Enterprise Value

For the Biotechnology subindustry, AgeX Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's Enterprise Value falls into.



AgeX Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

AgeX Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

AgeX Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics  (AMEX:AGE) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

AgeX Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=31.778/-9.911
=-3.21

AgeX Therapeutics's current Enterprise Value is $31.78 Mil.
AgeX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.91 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

AgeX Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=31.778/-9.78
=-3.25

AgeX Therapeutics's current Enterprise Value is $31.78 Mil.
AgeX Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.78 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

AgeX Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=31.778/0.142
=223.79

AgeX Therapeutics's current Enterprise Value is $31.78 Mil.
AgeX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (AgeX Therapeutics) Business Description

Traded in Other Exchanges
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Executives
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae officer: Chief Financial Officer C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May director 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West director, officer: Chief Executive Officer AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall officer: Corporate Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg officer: Vice President-Research 935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin director 3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd 10 percent owner 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik officer: Chief Operating Officer C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501